Abstract
The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune-driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence-related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging.
| Original language | English |
|---|---|
| Pages (from-to) | 1089-1122 |
| Number of pages | 34 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 79 |
| Issue number | 5 |
| Early online date | 18 Dec 2023 |
| DOIs | |
| Publication status | Published - May 2024 |
Bibliographical note
Publisher Copyright:© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Funding
We thank the EAACI Executive Committee for funding this taskforce. The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy); FRW received funding from by Danube Allergy Research Cluster‐DARC #08 of the Karl‐Landsteiner University, Krems, Austria. GN received funding by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aim well Charitable Trust (UK), The Israel Science Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); OP received funding from MICIIN (PID2020‐114396RB‐I00). MS has received research grants from the Swiss National Science Foundation (SNSF nr 310030_189334/1), GSK, Novartis and Stiftung vorm. Bündner Heilstätte Arosa.
| Funders | Funder number |
|---|---|
| Aim well Charitable Trust | |
| Danube Allergy Research Cluster‐DARC | |
| EAACI Executive Committee | |
| Emalie Gutterman Memorial Endowed Fund | |
| MICIIN | PID2020‐114396RB‐I00 |
| Novartis and Stiftung | |
| University of Salerno and Campania Region | |
| GlaxoSmithKline | |
| Medical Research Council | MR/T010371/1 |
| Engineering and Physical Sciences Research Council | EP/T003189/1 |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | 310030_189334/1 |
| FWF Austrian Science Fund | SFB F4606‐B28 |
| Ministerio de Economía y Competitividad | CM17/00140, RD16/0006/0001 |
| Ministero dell’Istruzione, dell’Università e della Ricerca | 2017MLC3NF_005 |
| Israel Science Foundation | |
| Instituto de Salud Carlos III | |
| Università degli Studi di Messina | |
| Regione Siciliana | |
| European Academy of Allergy and Clinical Immunology |
Keywords
- cell metabolism
- immune senescence
- immunometabolism
- inflammaging
- senolytic drugs
- senomorphic drugs